PPT-Fabry Disease: new therapies in 2019

Dr Michael L West Division of Nephrology Department of Medicine Dalhousie University Halifax NS Canada mlwestdalca Fabry Disease OMIM 301500 Glycosphingolipid Gb3 Most specific therapies in Fabry disease increase . . Spectrographs. Measurements . of the line shift.. a(. sin. a. sin. b. ). g. rating constant. Echelle. spectrometer. The first . standard grating . is optimized for a single lower . order. The . echelle. Is NOT Asthma. A Disease of the Sarcomere. Prevalence -- Alternative. Can Be Obstructive or Nonobstructive HCM. HCM Prevalence and Diagnostic Criteria. Diagnostic Challenges. Identifying HCM. Athlete's Heart vs HCM. Michael D. Weiss, M.D.. Professor of Pediatrics. Division of Neonatology. General Overview of the Network. Mission. The Florida Neonatal Neurologic Network’s (FN3) mission is to provide state-of-the-art care for newborn babies with brain injuries and to collect research and develop future therapies to improve long-term outcomes.. Week . 13, . 2019. You are encouraged to reuse our maps and graphs for your own purposes and free to translate, provided the content is not altered and the source is acknowledged. . 2. Distribution of confirmed and probable cases of Ebola virus disease and health zones reporting cases, North Kivu and . D. Craig Hooper, PhD, FNAI. Professor of Cancer Biology, SKCC, TJU. DouglasC.Hooper@Jefferson.edu. Therapeutic Modalities. Cancer immunotherapy. Hematologic disorders (non-malignant). Regenerative medicine. Maryam. . Banikazemi. , MD. Associate Prof of Pediatric and Genetics. New York Medical College . & . Shahid. . Beheshti. University. Overview of clinical & Diagnostic Approaches to Inherited Metabolic Disorders. the Beginning of an Uptick Related to Global Climate Change. Serum:. WBC count 6.4 x 10. 3. /mL. C-reactive protein <1.0 mg/mL. HIV p24 antigen and HIV 1+2 antibody screening negative . Treponemal antibody negative. IntroductionFabry disease (FD) arises from an X-linked defect in lipid storage, whereby deicient or -galactosidase A (-gal A) activity leads to systemic deposition of glyco-sphingolipids, mainly Page 64 of 69 FMNry diseMse: ProPoPype of IysosomMl SPorMge Gisorder RiPO sysPemic Hrene SMn-Román-MonserrMP*, JuMn-RMmón Gimeno-BlMnes Article InfoArticle Notes Fabry disease is a rare inherited m • What is Fabry Disease?• What Causes Fabry?• How Common is Fabry? Guide to Understanding Fabry Disease mps@mpssociety.or.ukwww.mpssociety.or.uk Dianosis of Fabry DiseaseFabry Dis Special thanks toShireThe full article and its related educational materialwere produced by and under the sole responsibility of the Working Group on Myocardial and Pericardial Diseases. ESC WORKING G RAPID RISK ASSESSMENTEbola virus disease outbreak in North Kivu and Ituri Provinces, Democratic Republic of the Congo Main conclusions The Ebola outbreak in the Democratic Republic of the Congo (DRC) Summary deck. 2. With over 7,000 medicines in development, the exciting new wave of medical innovation will play a key role in . addressing the challenges faced by patients and healthcare systems . Source: Health Advances analysis; Adis R&D Insight Database. March 2015, compiled by PhRMA. Supported by Sanofi Genzyme. Agenda. Pathogenesis of . Fabry. Disease. Evaluation of . Fabry. Disease. Fabry. Disease Management. Learning Objectives. Discuss the pathophysiology of . Fabry. disease and its impact on kidney function to increase awareness.